Dermatology News

Dermatology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Raasch B - Imiquimod 5% cream has been shown to stimulate the innate and cell mediated immune system. The short-term success of imiquimod 5% cream in randomized controlled trials comparing different treatment regimes and dosing as a treatment for small superficial basal cell carcinoma (BCC) not on the face or neck is in the range of 82% for 5 times per week application. A high proportion of participants with good response rates to topical treatment (58%–92%) experience local side effects such as itching and burning, less commonly erosion and ulceration, but the proportion of participants ceasing treatment has not been high.


Today in Clinical Pharmacology...keeping you current

Novel Therapies for Pemphigus Vulgaris: An Overview
Drugs & Aging, 09/21/09

A practical approach to using methotrexate
Dermatology in Practice, 10/09/09

Ustekinumab for the treatment of plaque psoriasis
Expert Review of Dermatology, 10/13/09

Today in Dermatologic Oncology...keeping you current

A practical approach to using methotrexate
Dermatology in Practice, 10/09/09

Positron emission tomography in early detection of relapse in high-risk melanoma patients: a retrospective review
Community Oncology , 10/09/09

Surgical excision margins for primary cutaneous melanoma
Cochrane Reviews, 10/09/09

Today in Dermatopathology...keeping you current

Erysipeloid: a review
Clinical and Experimental Dermatology, 09/18/09

Update on oral lichen planus
Expert Review of Dermatology, 10/14/09

A practical approach to using methotrexate
Dermatology in Practice, 10/09/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address